$MSA (MSA Safety Incorporated)

$MSA {{ '2015-11-10T18:14:11+0000' | timeago}} • Announcement

The Board of Directors of $MSA declared a fourth quarter dividend of $0.32 per share, payable on Dec. 10, 2015 to shareholders of record on November 23, 2015.

$AMGN {{ '2017-07-25T20:50:47+0000' | timeago}} • Infographic

$AMGN Amgen Earnings AlphaGraphic: Q2 2017 highlights

$IVC {{ '2017-07-25T16:39:52+0000' | timeago}} • Announcement

$IVC received notice from the FDA that the company has successfully satisfied the agency's requirements under the consent decree to resume full operations at its Corporate and Taylor Street manufacturing facility in Elyria, Ohio.

$ABT {{ '2017-07-25T15:58:08+0000' | timeago}} • Announcement

$ABT has announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a Xience everolimus-eluting coronary stent to unblock coronary arteries. Approx 2,000 patients at 100 sites in the US and Asia will be studied.

$LLY {{ '2017-07-25T15:33:57+0000' | timeago}} • Announcement

$LLY and its development and marketing partner $INCY announced that resubmission of rheumatoid arthritis drug baricitinib will be delayed beyond 2017 and at least it will take 18 months. FDA has demanded for a new trial. ELi Lilly added that baricitinib tablets have been approved since Feb 2017 in EU and the drug was approved recently in Japan.

$ATI {{ '2017-07-25T15:24:30+0000' | timeago}} • Announcement

$ATI has inked a Long-Term Purchase Agreement with Pratt & Whitney, a $UTX company, to supply isothermal forgings and nickel-based powder alloys for next-generation jet engines. The deal begins in 2017 and is expected to generate revenues in excess of $1Bil from 2017 to 2030.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

The drug maker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $2.80-21.40 from the prior guidance of $20.45-21.25.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$LLY {{ '2017-07-25T14:13:17+0000' | timeago}} • Announcement

$LLY, which joined hands with $NKTR recently to co-develop the autoimmune drug NKTR-358, cut down its GAAP earnings outlook for FY17 by $0.09 per share to $2.51-2.61. However, Eli Lilly lifted its non-GAAP EPS estimate to $4.10-4.20 from the prior outlook of $4.05-4.15 Revenue outlook also lifted to $22.0-22.5Bil from prior range of $21.8-22.3Bil.

$LLY {{ '2017-07-25T13:14:16+0000' | timeago}} • Announcement

Drugmaker $LLY reported a jump in its profit for the second quarter 2017, boosted by new pharma products sales and higher realized prices. Profit climbed 35% to $1.01Bil and GAAP EPS surged 34% to $0.91 versus a year ago. Revenue grew 8% to $5.82Bil and non-GAAP EPS spiked up 29% to $1.11.

$UTX {{ '2017-07-25T12:34:46+0000' | timeago}} • Announcement

$UTX said new equipment orders at Otis were flat for 2Q17 versus the prior year. Despite Carrier's plan to relocate fan coils manufacturing to Mexico and layoffs, orders at UTC Climate, Controls & Security increased by 11% organically. Commercial aftermarket sales were up 4% at Pratt & Whitney and were up 7% at UTC Aerospace Systems.

$LLY {{ '2017-07-25T12:32:52+0000' | timeago}} • Infographic

$LLY Eli Lilly and Company Earnings AlphaGraphic: Q2 2017 Highlights

$BIIB {{ '2017-07-25T12:18:23+0000' | timeago}} • Announcement

$BIIB Biogen Inc. Earnings AlphaGraphic: Q2 2017 Highlights

$UTX {{ '2017-07-25T12:16:57+0000' | timeago}} • Announcement

$UTX lifted its FY17 sales outlook to $58.5-59.5Bil from $57.5-59Bil, while narrowing its adjusted EPS guidance to $6.45-6.60 from $6.30-6.60. This is based on its strong year-to-date performance and outlook for the remainder of 2017. Following this, $UTX stock, which touched new 52-week of $124.79 recently, is trading higher in premarket session.

$UTX {{ '2017-07-25T12:12:05+0000' | timeago}} • Announcement

Following the uplift of dividend by 6.1% last month, $UTX's 2Q17 earnings came in-line with its expectations, on strategic priorities execution, including growth of its business through investments, aerospace backlog delivery, and cost reduction goals achievement. This was made despite maintaining a disciplined approach to capital allocation.

$UTX {{ '2017-07-25T12:07:01+0000' | timeago}} • Announcement

Diversified conglomerate $UTX reported a rise in 2Q17 earnings driven by lower income tax expenses, despite a rise in costs and expenses. Income from continuing operations rose 1% to $1.43Bil and EPS increased 5% to $1.80. Sales grew 3% to $15.3Bil, including a 3% organic growth. Adjusted EPS from continuing operations rose 2% to $1.85.

$UTX {{ '2017-07-25T11:34:00+0000' | timeago}} • Infographic

$UTX United Technologies Earnings AlphaGraphic: Q2 2017 Highlights.

$LLY {{ '2017-07-24T19:31:07+0000' | timeago}} • Announcement

As a result of the deal signed with Nektar on co-developing autoimmune drug NKTR-358, $LLY expects a charge of about $0.09 per share to its 2017 earnings. Eli Lilly cut down its 2017 GAAP EPS outlook by $0.09 to $2.51-2.61 from its previous outlook of $2.60-2.70 and it didn't change the estimate for non-GAAP EPS because of the Nektar partnership.

$LLY {{ '2017-07-24T18:19:30+0000' | timeago}} • Announcement

$LLY to co-develop $NKTR's autoimmune drug NKTR-358. Under the deal terms, Eli Lilly will pay Nektar Therapeutics an upfront payment of $150MM and up to $250MM if development and regulatory milestones are achieved. Nektar to complete Phase 1 clinical development and will bear 25% of Phase 2 cost. $LLY will bear 75% of the Phase 2 development cost.

Recent Transcripts

PHG (Koninklijke Philips N.V)
Monday, July 24 2017 - 8:00am
DOV (Dover Corporation)
Thursday, July 20 2017 - 2:00pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
NTIC (Northern Technologies International Corp.)
Thursday, July 13 2017 - 1:00pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
IVC (Invacare Corporation)
Tuesday, May 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
SNN (Smith & Nephew plc)
Friday, May 5 2017 - 7:30pm
MSI (Motorola Solutions, Inc.)
Thursday, May 4 2017 - 9:00pm
SPXC (SPX Corporation)
Thursday, May 4 2017 - 8:45pm
KAMN (Kaman Corporation)
Thursday, May 4 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
ROP (Roper Technologies, Inc.)
Friday, April 28 2017 - 12:30pm
TRS (TriMas Corporation)
Thursday, April 27 2017 - 2:00pm
CRY (CryoLife Inc.)
Thursday, April 27 2017 - 12:00pm
AMGN (Amgen Inc)
Wednesday, April 26 2017 - 9:00pm
AVY (Avery Dennison Corporation)
Wednesday, April 26 2017 - 4:00pm
EXAC (Exactech Inc.)
Wednesday, April 26 2017 - 2:00pm

AlphaGraphics you may like